Articles related to HEART FAILURE (HF)

The Heart Failure Society of America released a scientific statement establishing diagnostic criteria and a treatment framework for heart failure with mildly reduced ejection fraction, a phenotypically heterogeneous group historically underrepresented in dedicated interventional trials.

A single-institution case series of 13 biopsy-proven hydroxychloroquine cardiomyopathy patients documented variable outcomes after drug cessation, ranging from full functional recovery to progression requiring advanced heart failure therapies.

A year‑in‑review article highlights major cardiovascular themes from 2025, including evolving approaches to hypertension, myocardial infarction management, and atrial fibrillation care.

Studies on fluid restriction in patients with HF are scarce, and most of the available studies are at high risk of bias. Although power is lacking, there is no evidence indicating that fluid restriction affects mortality or HF hospitalizations, but there is a signal of harm in terms of thirst distress.

“CHIP, especially non-DNMT3A CHIP, was independently associated with incident HF. Future research should explore the gene-specific mechanisms by which CHIP variants promote HF in humans.” — Study Authors, JAMA Cardiology

“Patients hospitalized for HFrEF in US clinical practice are at very high risk of poor clinical outcomes, even when prescribed quadruple medical therapy.” — Dr. Stephen J. Greene, Duke Clinical Research Institute